Roflumilast(roe flu’ ma last)
Daliresp
PREGNANCY CATEGORY C
Drug Class
Phosphodiesterase-4 (PDE4) inhibitor
Therapeutic Actions
Selectively inhibits PDE4 activity, leading to an accumulation of intracellular cyclic AMP in lung cells. How this helps the COPD patient is not clearly understood.
Indications
Reduction of exacerbation risk in patients with severe COPD associated with chronic bronchitis and a history of exacerbation
Contraindications and Cautions
Contraindicated with known hypersensitivity to components of the drug, moderate to severe liver impairment, acute bronchospasm, pregnancy, lactation.
Use cautiously with a history of depression or suicide attempts.
Available Forms
Tablets—500 mcg
Dosages
Adults
500 mcg/day PO with or without food.
Pediatric patients younger than 18 yr
Safety and efficacy not established.
Patients with hepatic impairment
Contraindicated for patients with moderate to severe liver impairment (Child-Pugh class B or C).
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
